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Abstract External quality assurance (EQA) programmes
allow a laboratory to monitor independently its perfor-
mance and provide feedback to identify and investigate
potential areas of concern. However, both the definition of
appropriate ‘performance indicators’ and their statistical
analysis vary across EQA providers. Typically, perfor-
mance scores have an unknown statistical distribution and
hence arbitrary thresholds are used to measure perfor-
mance. In this paper, we introduce a scoring system based
on well-known statistical principles. The system is simple,
flexible and easy to interpret. It can be used to measure
performance for single samples or across a panel so pro-
viding useful and meaningful information to participants in
EQA programmes. The score is illustrated using the 2005
QCMD Hepatitis B Virus Proficiency programme.
Keywords Quality assessment  Scoring system 
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Introduction
External quality assessment (EQA) or proficiency testing
(PT) has long been considered the most important way of
monitoring laboratory quality. It provides a means of
monitoring the entire laboratory practice and procedure,
from receipt of sample through to the reporting of patient
results. It allows a laboratory to monitor independently
performance and also provides a feedback mechanism for
identifying and investigating potential areas of concern. As
a result, EQA has become an integral part of a laboratory’s
quality system requirements, complementing the internal
quality control and other quality assurance processes. In
addition, with many laboratories now working towards ISO
(International Standard Organisation) certification [1] and/
or accreditation [2], the need for appropriate EQA has
increased substantially. However, although there are spe-
cific guidelines [3–5] and general principles which are
common to most EQA schemes, there are many different
approaches to EQA. Different clinical, analytical, and
regulatory goals within different clinical laboratory ser-
vices and different technologies require variations in the
design, implementation, and reporting mechanism of the
EQA programme. Hence, it can often be difficult for a
clinical laboratory to judge which EQA scheme is best for
its specific needs and provide it with the most appropriate
way of monitoring its performance. Furthermore, the
identification of appropriate criteria or ‘performance indi-
cators’ to monitor and assess a laboratory can be
fundamentally difficult. Traditionally, clinical chemistry
has led on laboratory quality issues. However, with the
advent of new technologies such a nucleic acid-based
diagnostics and their rapid transition into the routine clin-
ical laboratory, particularly in microbiology, traditional
approaches to quality and EQA are often limited and
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difficult to apply. Therefore there is a need to adapt current
methods or define, develop, and implement new quality
rationale for EQAs. One of the greatest challenges is
defining suitable performance indicators and monitoring
performance in a clinical context as well as being able to
differentiate amongst good, average, and poor participating
laboratories. Within clinical microbiology, many EQA or-
ganisations providing schemes for the molecular diagnosis
of infectious diseases have focused on the traditional sub-
jective approach to EQA with peer group review and
consensus analysis [6] rather than on defined performance
indicators related to specific analytical and clinical
parameters. In addition, the lack of high quality reference
materials, internationally recognised standards, and suit-
able control material with which to monitor nucleic acid-
based measurement systems (assays) has meant that EQA
organisations have been compelled to use consensus-based
approaches in order to establish acceptable performance
limits.
To allow some internal comparison of laboratory per-
formance, type of technology and method used within an
EQA distribution the Quality Control for Molecular
Diagnostics (QCMD) organisation has historically used a
very simple scoring system for their EQA panels. The EQA
panels are designed containing samples with no, low,
medium and high microbial concentrations. The panels are
distributed to different laboratories worldwide. Laborato-
ries analyse the panels knowing the pathogens but blind to
the microbial concentrations. Results obtained by the lab-
oratory are returned to QCMD for analysis. The individual
laboratory scores were not reported but used for internal
report analysis only. The principal of the EQA programme
was non-judgemental and one of self determination.
However as regulatory requirements change, increasing
numbers of laboratories are asking for a performance score
to be provided with each EQA distribution. Although
International guidelines for EQA exist, understandably
there are no global criteria for what constitutes an
acceptable or unacceptable level of performance. Some
EQA organisations focus on accuracy and others on
repeatability. However, scoring is often on an arbitrary
scale and it does not take into consideration the technology,
method, and the clinical importance or, implication of a
particular result. In addition, within some EQAs the deci-
sion on whether to score results for a particular EQA
sample is dependant on the correct results obtained by a
high proportion of independent pre-testing laboratories,
those laboratories which have shown good performance in
previous years. In contrast, in other EQAs, an advisory
group may directly determine whether the reported results
are fit for purpose to use within that EQA distribution.
There are also EQAs which use a variation of these
approaches.
The QCMD Biostatistics working party evaluated
approaches to performance scoring within the QCMD EQA
programmes. The primary aim was to establish a suitable
mechanism for monitoring laboratory performance that
gave an appropriate representation of a laboratory’s result,
was simple and easy to interpret, had the ability to include
cumulative performance scores from different QCMD
EQA programmes, and most importantly provided useful
and meaningful information to the laboratories which take
part in EQA programmes. The approach taken was to uti-
lise a number of defined performance indicators and
provide feedback to the participants on various aspects of
their performance in relation to these performance indica-
tors within the various QCMD programmes. The principal
of the scoring mechanism is introduced here.
Method
We first investigate performance indicators for individual
samples within a panel and extend this to an overall per-
formance score for a panel.
We provide performance indicators for the estimation of
microbial concentration, sample repeatability and detection
of the microbe.
We assume that the EQA panel consists of J samples.
The jth, (j = 1,…,J), sample is assumed to have an esti-
mated target concentration, lj, and to be categorised as one
of ‘Strong positive’ (SP), ‘Positive’ (P), ‘Weak positive’
(WP) or ‘Negative’ (N) defined as having high, medium,
low and no microbial concentration. We also assume that
participant i, (i = 1,…,I), has reported a microbial con-
centration of xij for the sample j on a log10 scale and/or has
reported the sample to be ‘Negative’, ‘Not determined’ or
‘Positive’ (nominal (qualitative) measurement).
We start by describing performance indicator for
quantitative measurement analysis followed by the
description of a performance indicator of within laboratory
consistency and microbe detection. Finally, we explain
performance indicators for a panel.
Existing quantitative measurement performance
indicators for individuals samples
Simple and immediate measures of the performance of
participant i for sample j are available based on functions
of the error or deviation, dij = (xij - lj). Commonly used
functions of dij include the absolute deviation, |dij|, the
squared deviation, dij
2 and the percentage absolute deviation
100|dij|/lj [7]. These metrics can be used as a relative
measure to compare laboratories and are easy to compute
and interpret. However, their statistical distributions are not
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known and so it is difficult to determine limits to identify
participants that are performing satisfactorily. An alterna-
tive approach is to set acceptance limits, typically lj ± 0.5
[8]. However, for this measure, all values within the range
are regarded as equally good and those outside are uni-
formly bad. For example, if the target value, on a log10
scale, were 3, then all the values between 2.5 and 3.5 are
acceptable all others are not. So a value of 2.51 is
acceptable and scored the same as the target value of 3 and
a value 3.49. The values of 0, 3.51 and 6 are regarded as
equally unacceptable, even though their clinical signifi-
cance may be very different.
Proposed quantitative measurement performance
indicator for individual samples
The proposed quantitative measurement performance
indicators for individual samples is based on the stand-
ardised score of a laboratory’s estimated microbial
concentration for sample j, xij, from a set of data with






The proposed score for sample j for the ith participant is
defined as






The absolute value of zij is used as it is assumed that an
underestimation and overestimation by the same amount
indicates equally poor performance. The floor (integer part)
function with a maximum of three helps interpretation by
participants.
The possible values of z* are 0, 1, 2 and 3. The score 0–3
are presented to participants as ‘highly satisfactory’, ‘sat-
isfactory’, ‘unsatisfactory’ and ‘highly unsatisfactory’ and
may be visualised with an associated colour code, for
example: green, yellow, orange and red respectively.
Note that, in general, the mean, lj and the standard
deviation, rj of the microbial concentration of sample j are
not known.
Procedure to calculate quantitative measurement
performance indicators for individual samples
Outliers detection
Once participants have submitted their results and data
have been cleaned (based on a pre-defined Standard
Operation Procedure), participants may be classified into K
mutually exclusive and exhaustive strata (e.g. based on
technology used). For those strata with at least five
observations the standardised residuals are calculated.
Outliers are defined as those values with a standardised
residuals with absolute value greater than 3 [9]. When the
stratum has less than five observations, outliers are defined
as those values greater than 1.5 times the interquartile
range from the relevant quartile [10].
Outliers are removed from the data when calculating r^j;
the estimate of the standard deviation, used to obtain the
performance indicator zij
*.
Note that those technology groups with the minimum of
5 datasets are included in this score calculation if and only
if the groups contain at least four datasets after detecting
and removing outliers.
Mean estimation
The mean lj may be estimated by the sample mean, xj;
known as the consensus value. However, this estimate may
be biased towards the mean of the modal measurement
system used and may be influenced by poorly performing
laboratories [11]. Besides, the mean lj may be estimated
from the use of a limited number of ‘reference’ laboratories
prior to the distribution of the panel, but this estimate may
be inaccurate and biased towards the technology used by
them. Hence, the use of a more robust estimate such as a
trimmed mean may be more appropriate.
Here, we propose a Bayesian approach to provide a
more accurate and appropriate estimate that makes use of a
prior estimate target microbial concentration or sample
target concentration, 0j, for the jth sample. The prior
sample target concentration may be available prior to the
panel distribution by the EQA organisation. The proposed
estimate is based on the prior target information updated
with estimates provided by ‘reference’ laboratories to
obtain the ‘posterior information’. This is the distribution
around the most likely true concentration target based on
the information available.
Bayesian model description The prior information is
represented by the distribution of the unknown sample
target concentration, lj, and the observed information by
the estimated sample target concentration by reference
laboratories, yrj for the laboratory r with r = 1,…,R and
sample j. In the proposed performance indicator of indi-
vidual samples, it is assumed that the prior and observed
distributions are normal.
The prior distribution of lj is assumed to be Nð#j; s2j Þ:
The mean 0j is a defined prior target concentration for
sample j and the variance sj
2 is chosen to be 0.0625 for all
samples since this ensures that the 95% of the prior dis-
tribution lies within the interval 0j ± 0.5 [12].
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The distribution of yrj is defined as N(lj, fj
2) where fj
2 is
an unknown parameter having an Inverse Gamma distri-
bution with parameters a and b, IGamma(a, b). Since we do
not have proper prior information about fj
2, the parameters
a and b are taken to be 0.0001 corresponding to an non-
informative prior distribution. Note that other distributions
can be used for the unknown fj
2 [13].
The conditional posterior distribution for the target
concentration lj is the normal distribution [13],
N
f2j #j þ s2j
PR
r yrj








Therefore, the proposed estimate for the true value of
target concentration is
l^j ¼
f2j #j þ s2j
PR
r yrj
f2j þ s2j R
:
Standard deviation estimation
The standard deviation, rj, may be estimated by using sj,
the sample standard deviation. Assuming the participants
are a random sample of all diagnostics technologies users,
then sj
2 is an unbiased estimate of rj
2.
However, since participants may be classified into K
mutually exclusive and exhaustive strata (e.g. based on
technology used), a more accurate estimate of the pooled
standard deviation, rj, may be found by considering the
strata sizes and within strata standard deviations as shown
below.
If there are nk participants within stratum k(k = 1,
2,…,K) and their standard deviation for sample j is sjk, then
an unbiased estimate for rj







This is the value of the mean square for the error in the
ANOVA table when the response is the participant’s result
and the factor levels are the strata.
Depending on the objectives of the assessment, partici-
pants’ laboratories may be assessed with respect to the
estimate target concentration, consensus value or stratum
consensus value.
To illustrate how to calculate scores for an individual
sample, consider two laboratories, Lab1 and Lab2, with
estimated microbiological concentrations of 3.509 and
1.826, respectively. These resulted in standardised residu-
als of -0.658 and -3.520, respectively.
Lab2 is detected as an outlier as its standardised residual
is outside the interval (-3, 3). The individual score based
on the consensus concentration, technology consensus
concentration, target sample concentration (estimate
available by the EQA organisation) and the target con-
centration mean (Bayesian estimate for the sample
concentration) are calculated as follows:
• The consensus mean and standard deviation once
outliers are removed are calculated as 3.988 and
0.473. Therefore, the score is calculated in the follow-
ing way:








Alternatively, the target mean of 4 could be used resulting
in a z score for Lab1 of -1.038 and a z* score of 1. The
Bayesian estimate for the mean concentration is 4.469
yielding a z score for Lab1 of -2.029 and hence a z* score
of 2. The proposed score is flexible and instead the tech-
nology mean and standard deviation can be used. Their
estimates are 3.957 and 0.593, respectively. This leads to a
z score for Lab1 of -0.755 and thus a z* score of 0.
Proposed performance indicator of within laboratory
consistency
To assess the performance of within laboratory consistency
we suggest the following procedure:
• Calculate the difference of a laboratory’s results for two
samples, di.
• Estimate the standard deviation of the differences, r^d;








where sdk is the standard deviation, of the difference of
estimated microbial concentration for the two samples,
for the stratum k.
• Calculate the score, Zd*, based on the previous score
formula , where















where d^ is the known or estimated mean for the dif-
ference of microbial concentration for the two samples.
The interpretation of the score is equivalent to the
quantitative measurement score.
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Repeatability is a special case to monitor laboratory
consistency with d = 0. We define repeatability as a
laboratory producing the same estimate microbial con-
centration for two identical samples within a panel. Note
that repeatability score must not be added to obtain the
panel score since it is not independent to the scores of
individual samples of the panel. Repeatability score is extra
information about the ability to reproduce sample con-
centration concentrations.
Existing microbe detection performance indicators
for individual samples
A common measurement for scoring the performances of
participants with nominal (qualitative) response (‘Positive’,
‘Negative’) is to assign a score of 2 if the result is correct
and 0 if the result is incorrect or not determined. However,
the severity of the error is not taken into account
(e.g. reporting a negative sample when the sample contains
high microbial concentration should be penalised more
than reporting a negative sample when the sample contains
low microbial concentration).
Proposed microbe detection performance indicator
for individual samples
The proposed score for an individual sample ranges from 0
to 3 as defined in Table 1. This performance indicator takes
into account the severity of the error.
Proposed performance indicator for a panel
The proposed performance indicator for an individual
sample ranges from 0 (highly satisfactory) to 3 (highly
unsatisfactory). One measure of overall performance for a
panel is to sum a participant’s score for those samples
where a value is reported. The distribution of this score is
not known and will vary according to the number of
samples reported. Participants are classified using the
method outline below.
Quantitative measurement results
Assuming normality and independence, the proposed score
for an individual sample takes the value 0–3 with proba-
bilities 0.683, 0.272, 0.043 and 0.002, respectively. J
columns of ten thousand Monte Carlo simulations from the
above probability mass function are found to replicate
10000 virtual participants. The frequencies for these sums
are found. For consistency with the scoring for individual
samples, participants that reported J samples are given
score 0 (classified as ‘highly satisfactory’) if their sum is
in the smallest 68.3% of the simulated values, score 1
(‘satisfactory’) in the next 27.2%, score 2 (‘unsatisfactory’)
in the following 4.3% and score 3 (‘highly unsatisfactory’)
in the highest 2%. Table 2 gives the range of total scores
corresponding for each panel score for given number of
samples. For example, a participant with a total score of six
or seven from seven samples would be scored 2
(unsatisfactory).
Microbe detection results
A similar approach is taken for the panel score for microbe
detection data. For each sample, j, we observe a proportion
pj of participants with the correct response. Ten thousand
observations from a Bernoulli trial with probability
(1 - pj) are simulated. These are then multiplied by 3 (for
a strong positive or negative sample) or 2 (for a positive
sample). The results for each sample are summed and the
panel score ranging from 0 (highly satisfactory) to 3
(highly unsatisfactory) is based on the cumulative 68, 95,
Table 1 Penalty score table for microbe detection analysis
Sample category Participant’s result
Negative Not determined Positive
Strong positive 3 3 0
Positive 2 2 0
Weak positive 1 1 0
Negative 0 3 3




0 1 2 3
1 0 1 2 3
2 0 1 2–3 4?
3 0–1 2 3–4 5?
4 0–1 2–3 4–5 6?
5 0–1 2–4 5–6 7?
6 0–2 3–4 5–7 8?
7 0–2 3–5 6–7 8?
8 0–3 4–5 6–8 9?
9 0–3 4–6 7–8 9?
10 0–4 5–6 7–9 10?
11 0–4 5–7 8–10 11?
12 0–4 5–7 8–10 11?
13 0–5 6–8 9–11 12?
14 0–5 6–8 9–12 13?
15 0–6 7–9 10–13 14?
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99 and 100% cut off points for the sum of the scores for all
samples in the panel. For example, a participant that was
within the 68% group of participants with the lowest
summed score would have a panel score of 0.
Results and application
Here, we present an application of the proposed perfor-
mance indicators to the 2005 QCMD Hepatitis B Virus
Proficiency Programme [14]. The Panel composition is
shown in Table 3. Prior to the distribution of the panel, a
total of 7 panels were analysed by independent ‘reference’
laboratories. A total of 122 data sets were received (all had
microbe detection data whilst 101 also included microbi-
ological concentration estimates) from 116 participants
within 27 countries.
The datasets were classified per technology groups used
to analyse the panel: conventional commercial PCR (CC,
n = 38), Conventional In-house PCR (CIH, n = 12), Real
time Commercial PCR (RTC, n = 39), Real time In-house
PCR (RTIH, n = 24), bDNA (bDNA, n = 7) and Hybrid
Capture (HC, n = 2). However, the total number of datasets
reporting quantitative measurement data per technology
group varied depending on the sample analysed.
Quantitative measurement analysis
We present a summary of the quantitative measurement
score obtained with respect to consensus and technology
group consensus sample concentration.
Note that the negative samples and values reported as
outside the detection limits of the measurement systems
were excluded from the quantitative measurement analysis.
Additionally, all laboratories except those with results
outside the limit of detection of the measurement system
are scored even if they were not included for the calcula-
tion of the standard deviation.
Score with respect to consensus sample concentration
The consensus mean xj and standard deviation, r^j; for each
positive sample were calculated (datasets provided by
laboratories using HC technologies and outliers were not
included for the calculations). We used four technology
groups: CC, RTC, RTIH and bDNA, to estimate the stan-
dard deviation for samples HBV01, HBV02, HBV04,
HBV06 and HBV08. However, we did not have enough
datasets (C5) to take into account the bDNA group for
samples HBV03 and HBV05 since some estimates were
outside the limit of detection for the measurement system.
Table 4 shows the estimated mean and standard devia-
tion of the log microbial concentration and the frequency of
z* scores for each sample with respect to the consensus.
Score with respect to technology consensus mean
We calculate the consensus mean for each technology
group with at least four observations once outliers have
been removed. Each laboratory, associated with a tech-
nology group, is scored with respect to the consensus mean
and the estimated standard deviation of that technology
group. CIH and HC technology groups do not satisfy the
requirement of at least five datasets before and four data-
sets after outliers removal. Therefore, laboratories using
these technologies are excluded for scoring with respect
their technology group.
Table 5 shows the estimated mean and standard devia-
tion of the log microbial concentration and the frequency of
z* scores for each sample by technology.
Scoring performance within laboratory consistency
As an illustrative example, we consider sample HBV01 and
HBV04, both of which are subtype D with targets 5.00 and
4.00 log10 copies/mL, respectively. The consensus mean
and standard deviation of the difference after removal of
outliers are 0.942 and 0.230, respectively. Therefore, the
difference, z value and the score for laboratory consistency
of a laboratory with observations 4.954 and 3.923 for
samples HBV01 and HBV04, respectively are:
d ¼ 1:031; zd ¼ 1:031  0:942
0:230
¼ 0:387 and zd ¼ 0:
Microbe detection analysis
Table 6 shows the total number of datasets per technology
group and percentage of datasets with a score of 0, 1, 2 and
3 per sample.








HBV06 D 6.00 SP
HBV08 A 5.00 P
HBV01 D 5.00 P
HBV02 A 4.00 P
HBV04 D 4.00 P
HBV05 A 3.00 WP
HBV03 D 3.00 WP
HBV07 N/A 0.00 N
SP Strong positive, P positive, WP weak positive, N negative
QCMD concentration unit = log10(N) where N is the number of
copies in 1 mL sample solution
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Panel score
QCMD only provides a panel score to those laboratories
that report the estimated concentrations for all positive
samples. Thus, panel scores for quantitative measurement
analysis were found for the 56 laboratories which returned
estimates for all seven positive samples. Of these, 47
datasets received a panel score 0, 2 datasets obtained score
1, 3 datasets obtained score 2 and 4 datasets obtained score
3.
Discussion
EQA is an important mechanism for laboratories to mea-
sure their performance of the entire process. However,
performance indicators used by EQA providers varies with
limits set for good performance arbitrary often without
documented statistical justification. Typical performance
indicators consider the detection of a microbe, repeatability
and the accuracy of microbial concentration estimates. In
this section, we consider each of these in turn concentrating
on their scoring schemes.
Microbe detection
In contrast to many EQA schemes, in this paper, we pro-
pose a score for detecting a microbe within the sample that
takes into account the microbial concentration. This
penalises the failure to detect a sample with a high
microbial concentration more than failing to detect a low
microbial concentration. Clearly, defining the categories
Table 4 Summary Laboratories’ Score with respect to estimated consensus concentration
Consensus Conventional commercial PCR (CC) n = 32 Conventional in-house PCR (CIH) n = 4
Mean SD 0 1 2 3 LOD/NRa 0 1 2 3 LOD/NRa
HBV06 5.702 0.607 16 3 1 0 12 3 0 1 0 0
HBV08 4.887 0.511 29 2 0 0 1 0 1 2 1 0
HBV01 4.789 0.576 31 0 1 0 0 1 1 1 1 0
HBV02 3.988 0.473 28 4 0 0 0 2 0 2 0 0
HBV04 3.834 0.544 29 2 1 0 0 0 1 2 1 0
HBV05 2.952 0.576 29 2 0 0 1 1 1 0 0 2
HBV03 2.879 0.453 28 3 0 0 1 1 0 3 0 0
Consensus Real time commercial (RTC) n = 35 Real time in-house (RTIH) n = 20
Mean SD 0 1 2 3 LOD/NRa 0 1 2 3 LOD/NRa
HBV06 5.702 0.607 22 9 3 1 0 14 4 0 2 0
HBV08 4.887 0.511 21 10 2 2 0 13 2 3 2 0
HBV01 4.789 0.576 21 9 1 4 0 14 2 2 2 0
HBV02 3.988 0.473 21 10 2 2 0 12 4 2 2 0
HBV04 3.834 0.544 20 11 0 3 1 12 6 1 1 0
HBV05 2.952 0.576 19 8 6 0 2 12 2 1 0 5
HBV03 2.879 0.453 16 12 2 1 4 9 5 1 1 4
Consensus bDNA n = 7 Hybrid capture (HC) n = 2
Mean SD 0 1 2 3 LOD/NRa 0 1 2 3 LOD/NRa
HBV06 5.702 0.607 7 0 0 0 0 2 0 0 0 0
HBV08 4.887 0.511 7 0 0 0 0 0 0 0 0 2
HBV01 4.789 0.576 7 0 0 0 0 0 0 0 0 2
HBV02 3.988 0.473 7 0 0 0 0 0 0 0 0 2
HBV04 3.834 0.544 7 0 0 0 0 0 0 0 0 2
HBV05 2.952 0.576 0 1 0 0 6 0 0 0 0 2
HBV03 2.879 0.453 0 0 0 0 7 0 0 0 1 1
CC commercial PCR, CIH conventional in-house PCR, RTC real time commercial PCR, RTIH real time in-house PCR, HC hybrid capture
a LOD/NR: result reported as lower limit detection or upper limit detection/no value or not result reported
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Table 5 Summary laboratories’ score with respect to estimated technology consensus concentration
Technology CC n = 32 Technology bDNA n = 7
Mean SD 0 1 2 3 LOD/NRa Mean rj 0 1 2 3 LOD/NR
a
HBV06 5.721 0.496 6 12 2 0 12 5.940 0.035 5 2 0 0 0
HBV08 5.068 0.241 27 3 1 0 1 5.161 0.092 6 1 0 0 0
HBV01 4.967 0.281 28 1 2 1 0 5.004 0.069 5 2 0 0 0
HBV02 4.121 0.253 26 3 3 0 0 4.163 0.140 4 3 0 0 0
HBV04 4.017 0.291 26 5 1 0 0 3.988 0.125 5 2 0 0 0
HBV05 3.102 0.257 29 2 0 0 1 – –
HBV03 2.976 0.255 14 16 1 0 1 – –
Technology RTC n = 35 Technology RTIH n = 20
Mean SD 0 1 2 3 LOD/NRa Mean rj 0 1 2 3 LOD/NR
a
HBV06 5.637 0.720 24 9 1 1 0 5.676 0.574 13 4 1 2 0
HBV08 4.874 0.679 22 11 1 1 0 4.700 0.568 14 4 0 2 0
HBV01 4.697 0.799 24 7 3 1 0 4.641 0.563 13 4 1 2 0
HBV02 3.957 0.593 24 9 0 2 0 3.788 0.577 14 3 2 1 0
HBV04 3.763 0.716 23 8 2 1 1 3.806 0.609 12 7 0 1 0
HBV05 2.794 0.754 22 11 0 0 2 2.937 0.601 12 2 1 0 5
HBV03 2.836 0.564 19 11 0 1 4 2.855 0.525 9 6 0 1 4
CC commercial PCR, RTC real time commercial PCR, RTIH real time in-house PCR
a LOD/NR: result reported as lower limit detection or upper limit detection/no value or not result reported
Table 6 Summary microbe detection laboratories’ score
Defined CC, n = 38 CIH, n = 12 RTC, n = 39
Status 0 1 2 3 0 1 2 3 0 1 2 3
HBV06 SP 38 0 0 0 12 0 0 0 39 0 0 0
HBV08 P 38 0 0 0 12 0 0 0 39 0 0 0
HBV01 P 38 0 0 0 12 0 0 0 39 0 0 0
HBV02 P 38 0 0 0 12 0 0 0 39 0 0 0
HBV04 P 38 0 0 0 12 0 0 0 38 0 1 0
HBV05 WP 36 2 0 0 8 4 0 0 37 2 0 0
HBV03 WP 35 3 0 0 10 2 0 0 34 5 0 0
HBV07 N 38 0 0 0 12 0 0 0 38 0 0 1
Defined RTIH, n = 24 bDNA, n = 7 HC, n = 2
Status 0 1 2 3 0 1 2 3 0 1 2 3
HBV06 SP 24 0 0 0 7 0 0 0 2 0 0 0
HBV08 P 24 0 0 0 7 0 0 0 0 0 2 0
HBV01 P 23 0 1 0 7 0 0 0 0 0 2 0
HBV02 P 23 0 1 0 7 0 0 0 0 0 2 0
HBV04 P 23 0 1 0 7 0 0 0 0 0 2 0
HBV05 WP 18 6 0 0 3 4 0 0 0 2 0 0
HBV03 WP 19 5 0 0 2 5 0 0 1 1 0 0
HBV07 N 22 0 0 2 6 0 0 1 1 0 0 1
CC commercial PCR, CIH conventional in-house PCR, RTC real time commercial PCR, RTIH real time in-house PCR, HC hybrid capture
SP strong positive, P positive, WP weak positive, N negative
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strong positive, positive and weak positive is open to
debate. This may be done using a combination of clinical
relevance and by considering the proportion of participants
detecting the microbe (e.g. at least 95% of participants
must detect the microbe for the sample to be defined as a
strong positive).
The individual samples scores for the proposed measure
are summed to form a panel score. We suggest that Monte
Carlo methods are used to simulate 10000 virtual users using
the probabilities of detecting a microbe estimated from
participants. These are summed and used to distinguish
between good, average and poorly performing laboratories.
Estimation of microbial concentration
In contrast to many EQAs that exclusively use a consensus
mean, we suggest a Bayesian approach to estimate the
target value. The Bayesian estimate is the value suggested
by the EQA provider (from internal investigations and
previous panels) amended by estimates from reference
laboratories. Although these too may contain measurement
system bias, care can be taken to ensure a range of mea-
surement systems are covered by the reference laboratories.
We suggest a measure that uses a more accurate measure
of the target value (see above) and a function of the labo-
ratory’s absolute deviation from the target. We find the score
by dividing the absolute deviation by the standard deviation
once the systematic error caused by different technologies
has been removed. To ease interpretation by laboratories the
integer value is found and capped at 3. We have shown (data
not reported) that once outliers are removed, the log10 values
from participants approximately follow a normal distribu-
tion. Hence, we can apply well-known statistical results to
this simple, robust measure. It should be noted that good
laboratories score low marks for the proposed score but high
marks for many existing measures.
The scoring system described here allows for evaluation
by technology type and therefore reduces the impact of
technology bias.
The proposed measure is the first to use Bayesian
techniques to estimate the target value and to incorporate
the variation attributable to different examining system
technologies. It is flexible as the target value may be
replaced by the technology consensus. For this application
the laboratories are being assessed on how close their
estimate is to the mean of other users of the same tech-
nology rather than the target. Hence, using this measure,
potential measurement system bias is ignored.
Repeatability
Some EQA providers concentrate on repeatability. For
example a laboratory may be regarded as adequate if its
reported difference from two samples is within 0.5 of the
median difference of all participants. Note that a laboratory
that under (or over) estimates both samples by the same
amount would be regarded as adequate in this example.
This would be the case even if the estimates were far from
the true value. Note also that no use is made of the different
technologies used.
Our flexible proposed scoring system could be easily
adapted to assess repeatability by using the difference
between two measurement systems. For identical samples
the target difference is zero. For non-identical samples the
target difference can be estimated from the difference
between the Bayesian estimates of the two samples.
The scores from individual samples of either the esti-
mated microbial concentration or repeatability measures
can be summed across the positive samples in the panel.
The use of Monte Carlo simulation using the well-known
properties of the normal distribution can be used to classify
laboratories as highly satisfactory to highly unsatisfactory.
This feedback is more informative and statistically rigorous
than currently available.
Drawbacks of the proposed approach
The proposed score provides a flexible, statistically rigor-
ous metric to assess laboratory performance for examining
system nucleic acid-based diagnostic users. There are some
drawbacks when considering quantitative measurement
results.
First, the score requires participants to provide their
estimate of the microbial concentration. Sometimes, par-
ticipants report values as outside the detectable limits of
the measurement system they used. These have been
ignored for the purposes of this paper. Possible approaches
to this problem include using censored value techniques or
to replace the value by either the limit of detection or half
this value.
Second, the score is only appropriate for positive sam-
ples. The score assumes normality, which is almost
certainly not valid for reported false positives from nega-
tive samples. The low frequency of these makes testing for
normality suspect.
Conclusions
The application of these performance indicators to the 2005
QCMD Hepatitis B Virus Proficiency programme high-
lights the flexible use and desirable properties of the
proposed scoring system for assessing various aspects of
laboratory performance.
The proposed scoring system for assessing laboratory
performance cannot only be applied to the field of
Accred Qual Assur (2009) 14:243–252 251
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microbiology but it can be applied to other EQA
programmes from the field of laboratory medicine to
chemistry where the normality assumption of the data is
verified.
The Monte Carlo approach for panel scores can be used
in any EQA programme where numeric performance scores
are given to individual samples.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
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